Advertisement


Matthew J. Ellis, PhD, MB, BCh, on Breast Cancer: Results of the FALCON Trial

2016 ESMO Congress

Advertisement

Matthew J. Ellis, PhD, MB, BCh, of the Baylor College of Medicine, discusses phase III study findings on fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced disease. (Abstract LBA14)



Related Videos

Skin Cancer

Omid Hamid, MD, on Melanoma: Results From the KEYNOTE-002 Study

Omid Hamid, MD, of The Angeles Clinic and Research Institute, discusses survival data from this clinical trial on pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory melanoma. (Abstract 1107O) Follow him on Twitter: @omidhamidmd

Breast Cancer

Judith Balmaña, MD, PhD, on Metastatic Breast Cancer: Study Results on Lurbinectedin (Spanish Language Version)

Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses in Spanish the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)

Prostate Cancer

Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)

Prostate Cancer

Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk prostate cancer. (Abstract 717O)

Skin Cancer

Alexander Eggermont, MD, PhD, on Melanoma: Results From the EORTC 18071 Trial

Alexander Eggermont, MD, PhD, of Gustave Roussy, discusses final overall survival findings on ipilimumab vs placebo after complete resection of stage III melanoma. (Abstract LBA2)

Advertisement

Advertisement




Advertisement